 |
 Michael Cohen
President, Chief Executive Officer, Chairman of the Board
Michael Cohen is the founder of our company and our predecessor company National stem Cell Inc. Mr. Cohen has earned his B.S. From Haifa University and began his career as a paramedic for NYC EMS in. He joined Americorp Securities as a Vice President in its mergers and acquisitions department in 1994. He was instrumental in launching a number of successful IPOs at Americorp Securities. He was recruited by Dafna Construction in 1995 as its CFO and played a principal role in its growth and subsequent purchase. In 1997, Mr. Cohen joined Citigroup as a Vice President of Corporate Finance and managed a department in the risk management division of Salomon Smith Barney. Mr. Cohen serves as our Chairman of the Board and President as well as one of our Principal Investigators for most of our therapeutic developments. |
| Back to Top |
 |
Ian McNiece
Ph.D., Chief Scientific Officer, Director
Dr. McNiece received his PhD in 1986 from the University of Melbourne undertaking his thesis work in studies of blood cell development at the Peter MacCallum Cancer Institute in Melbourne, Australia. He moved to the USA in July of 1986 to the University of Virginia as a postdoctoral fellow. In August 1998 he started working at Amgen Inc, as a Research Scientist and then as a Laboratory Head. In September 1997, he left Amgen and moved to the University of Colorado as the Director of Research in the Bone Marrow Transplant Program. Subsequently, he moved to Johns Hopkins University as a Professor of Oncology and Laboratory Director of the Graft Engineering Laboratory from January 2003 to May 2007. This laboratory is responsible for all processing of bone marrow, peripheral blood progenitor cell (PBPC) products and cord blood products for transplantation of cancer patients. He was actively involved in optimization of cellular grafts for patient treatment and the translation of basic research to clinical treatment. In July, 2007 he joined the Stem Cell Institute at the University of Miami as Director of the Experimental and Clinical Cell-Based Therapies and is presently Professor of Medicine at the University of Miami. |
| Back to Top |
|
Jason Isaacs
Secretary
Jason Isaacs joined as Secretary in June of 2010. Mr. Isaacs brings over thirteen years of legal experience. Mr. Isaacs is General Counsel of Green Hills Software, Inc., the largest independent provider of real time operating systems and embedded software development tools. Mr. Isaacs has a wide base of legal experience managing and protecting intellectual property resources, negotiating technology transactions with major corporations and governments, and complying with applicable laws and regulations. Mr. Isaacs practiced law at Brobeck Phleger & Harrison LLP and Heller Ehrman LLP in San Diego, specializing in technology transactions, licensing arrangements and business litigation in his representation of high growth and venture backed companies. Mr. Isaacs received his law degree from Harvard Law School, cum laude, and a B.A. from Brown University, magna cum laude, Phi Beta Kappa. |
| Back to Top |
|
Steven Byle
Director
Steven Byle joined our board of directors on January 5, 2009. Mr. Byle brings twenty years of experience in technology development and corporate management in the international market. Mr. Byle is a successful entrepreneur, engineer, and patent attorney for a diverse array of international, public and private, ventures. Mr. Byle is presently the Vice President of Technology for Dockwise, a public energy services company on the Euronext Amsterdam exchange (DOCKW:NA) with annual revenues exceeding US $500 million. Mr. Byle is also a founder and Member of the Board for a diverse group of companies, including: Pantheon Energy, an alternative energy company in Europe, Core International Group, a Cyprus company performing international manufacturing, logistics and distribution with plants in India and Malaysia, and Texas Auto Superstore, an online auto dealer in the United States. Mr. Byle speaks Spanish and Mandarin Chinese fluently, holds a J.D. degree with Honors in law from the University of Texas School of Law, specializing in Intellectual Property Law, and holds a B.S. degree in Engineering from the University of Michigan, summa cum laude as a prestigious Angell Scholar. |
| Back to Top |
|
Roger Fidler Esq.
Corporate Council
Mr. Fidler has been engaged in the private practice of law since 1983, specializing in corporate and securities law. Mr. Fidler was the sole director, President, Chief Executive and Financial Officer of Global Agri-Med Technologies, Inc., a corporation that is publicly traded in the pink sheets, since inception in October 28, 1999 until January 11, 2010. Mr. Fidler has previously served on the Boards of Directors and as an officer of several other publicly held corporations, including Diehl Graphsoft, Inc., D-Lanz Development Group, Inc., the Leonard Swindbourne Acquisition Corp., and numerous private companies. Mr. Fidler received a B.S. degree in Physics from Dickinson College, Carlisle, Pennsylvania in 1972; a Masters of Science degree from the University of Illinois at Champaign-Urbana, Illinois in 1974; and a Juris Doctor from the University of South Carolina in 1977 where he was a member of the Law Review. He is a member of the bars of New Jersey, New York and the District of Columbia and has practiced before the federal and state courts in New York and New Jersey as well as pro hac vice in cases before Federal District Courts in Kentucky and Florida. In addition he is a patent attorney authorized to practice before the United States Patent and Trademark Office. |
| Back to Top |
|
